JBT Marel Corp. 10-Q Summary: Q2 2026
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026, for JBT Marel Corporation (NYSE: JBTM). The Company is a global provider of technology solutions for the food and beverage industry, operating through two segments: Protein Solutions and Prepared Food and Beverage Solutions. The reporting period follows the 2025 acquisition of Marel hf., which was fully integrated into the Company's operations.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenue | $981 | $935 | $1,917 | $1,789 |
| Net Income | $28 | $3 | $73 | $(170) |
| Diluted EPS | $0.54 | $0.07 | $1.40 | $(3.27) |
| Operating Income | $46 | $48 | $114 | $15 |
| Adjusted EBITDA | $168 | $156 | $310 | $268 |
| Operating Cash Flow (YTD) | $221 | $137 | $221 | $137 |
| Free Cash Flow (YTD) | $179 | $106 | $179 | $106 |
| Total Debt (Gross) | $1,705 | $1,882 | $1,705 | $1,882 |
| Cash & Equivalents | $93 | $168 | $93 | $168 |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2026 revenue increased 4.9% year-over-year, driven by organic growth ($27M) and favorable foreign currency translation ($19M). The Protein Solutions segment saw a 10.9% revenue increase, while Prepared Food and Beverage Solutions remained flat.
- Profitability: Net income surged to $28M from $3M in Q2 2025. This improvement is largely due to the absence of a $147M one-time pension settlement charge recorded in Q1 2025 and lower interest expenses.
- Impairment Charge: The Company recorded a $33 million non-cash impairment charge in Q2 2026 related to acquired intangible assets in the Protein Solutions segment, impacting operating income.
- Debt Reduction: Total debt decreased as the Company repaid $403M in 2026 Convertible Senior Notes at maturity in Q2 2026. Interest expense, net, declined 55.2% year-over-year.
- Segment Performance: Protein Solutions Adjusted EBITDA margin expanded 350 bps to 24.0%, while Prepared Food and Beverage Solutions margin contracted 70 bps to 17.5% due to productivity inefficiencies.
Guidance, Outlook, and Risks
- Outlook: Management expects year-over-year growth in revenue, margins, and EPS for the full year 2026, supported by a record backlog and operational improvements. Capital expenditures for 2026 are projected between $105M and $120M.
- Restructuring: The "JBT Marel 2025 Integration restructuring plan" has incurred $41M in cumulative charges. Total estimated costs are $55M-$60M, with remaining costs expected to be recognized by year-end 2026. Cumulative savings are projected at $65M-$75M.
- Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of June 30, 2026, due to unremediated material weaknesses in IT general controls and journal entry processing inherited from the Marel acquisition. A remediation plan is underway.
- Risks: Key risks include inflationary pressures, supply chain disruptions, foreign currency fluctuations, and the ability to successfully integrate Marel and remediate internal control weaknesses.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for material weaknesses in IT and journal entry controls, as this impacts financial reporting reliability.
- Intangible Asset Impairment: Review the specific drivers of the $33M impairment charge in the Protein Solutions segment to assess future goodwill risks.
- Debt Covenants: Confirm continued compliance with the Second Amended and Restated Credit Agreement covenants (leverage and interest coverage ratios) given the debt structure.
- Segment Margins: Monitor the Prepared Food and Beverage Solutions segment for signs of operational efficiency recovery, as margins declined in Q2.
- Backlog Conversion: Assess the conversion rate of the "record backlog" into revenue to validate full-year growth guidance.